BELKIN Vision has announced the FDA clearance for its glaucoma laser, the Eagle device. The Eagle, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser, is designed for selective laser trabeculoplasty (SLT). This FDA clearance signifies a significant advancement in ophthalmology, expanding treatment options for the 70 million people worldwide affected by glaucoma, including over 3.6 million in the US alone.

As a pioneering contactless laser for glaucoma, the Eagle provides an automated and non-invasive solution for both patients and healthcare professionals. The American Academy of Ophthalmology recognizes laser trabeculoplasty as a valuable therapy for primary open-angle glaucoma. The Eagle distinguishes itself by delivering laser energy through the limbus to the trabecular meshwork without requiring a gonioscopy lens. The device's automated targeting and eye tracker that compensates for movement further enhance its advantages.

The company's Direct-SLT (DSLT) technology introduces a streamlined and user-friendly approach, aiming to broaden access to early laser therapy by enabling more eye care professionals to perform the procedure. Daria Lemann-Blumenthal, BELKIN Vision CEO, expressed gratitude for the team's skill and dedication, emphasizing the positive impact of FDA clearance on glaucoma patients' lives. The approval opens up novel treatment methods, providing renewed hope for those affected by this leading cause of irreversible blindness.